DERIVING HUMAN ENS LINEAGES FOR CELL THERAPY AND DRUG DISCOVERY IN HIRSCHSPRUNG'S DISEASE

• Published in: Nature (London) Vol. 531; no. 7592; pp. 105 - 109
• Main Authors: Fattahi, Faranak, Steinbeck, Julius A, Kriks, Sonja, Tchieu, Jason, Zimmer, Bastian, Kishinevsky, Sarah, Zeltner, Nadja, Mica, Yvonne, El-Nachef, Wael, Zhao, Huiyong, de Stanchina, Elisa, Gershon, Michael D., Grikscheit, Tracy C., Chen, Shuibing, Studer, Lorenz
• Format: Journal Article
• Language: English
• Published: 10.02.2016
• ISSN: 0028-0836; 1476-4687
• DOI: 10.1038/nature16951

The enteric nervous system (ENS) is the largest component of the autonomic nervous system with neuron numbers surpassing those present in the spinal cord 1 . The ENS has been called the “second brain” 1 given its autonomy, remarkable neurotransmitter diversity and complex cytoarchitecture. Defects in ENS development are responsible for many human disorders including Hirschsprung's disease (HSCR). HSCR is a caused by the developmental failure of ENS progenitors to migrate into the GI tract in particular the distal colon 2 . Human ENS development remains poorly understood due to the lack of an easily accessible model system. Here we demonstrate the efficient derivation and isolation of ENS progenitors from human pluripotent stem cells (hPSCs) and their further differentiation into functional enteric neurons. In vitro derived ENS precursors are capable of targeted migration in the developing chick embryo and extensive colonization of the adult mouse colon. In vivo engraftment and migration of hPSC-derived ENS precursors rescues disease-related mortality in HSCR mice (EDNRB s-l/s-l ), though mechanism of action remains unclear. Finally, EDNRB null mutant ENS precursors enable modeling of HSCR-related migration defects and the identification of Pepstatin A as candidate therapeutics. Our study establishes the first hPSC-based platform for the study of human ENS development and presents cell and drug-based strategies for the treatment of HSCR.